Endocrine Therapy

Breast Cancer Awareness Month is observed every October.

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.

Women with unilateral breast cancer who underwent bilateral mastectomy had a significantly lower risk for contralateral breast cancer than those who underwent other surgical procedures, results of a cohort study showed.

Women treated for breast cancer exhibited highly prevalent and distressing sexual health concerns, according to results of the WISH-BREAST study presented at ASCO Annual Meeting.

Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.

Compared with standard-of-care chemotherapy, trastuzumab deruxtecan demonstrated a statistically significant improvement in PFS among certain patients with metastatic breast cancer, according to a press release from the manufacturer.

Like women, men with hormone receptor-positive breast cancer have mortality risks that persist 20 years after diagnosis, with age, tumor size and grade, and nodal status playing factors, according to findings published in JAMA Oncology.

A woman in her late 50s is currently receiving treatment for her second bout of breast cancer. She is thought to be in remission, but Neelam Desai, MD, worries about more than just the disease.

SAN ANTONIO — The addition of ribociclib to endocrine therapy conferred durable benefit to patients with hormone receptor-positive, HER2-negative early breast cancer, according to findings presented at San Antonio Breast Cancer Symposium.

For many breast cancer survivors, adjuvant endocrine therapy can substantially reduce the risk for recurrence.